1. 5‐HT2B receptor antagonists attenuate myofibroblast differentiation and subsequent fibrotic responses in vitro and in vivo. Issue 15 (1st August 2016) Authors: Löfdahl, Anna; Rydell‐Törmänen, Kristina; Müller, Catharina; Martina Holst, C.; Thiman, Lena; Ekström, Gunilla; Wenglén, Christina; Larsson‐Callerfelt, Anna‐Karin; Westergren‐Thorsson, Gunilla Journal: Physiological reports Issue: Volume 4:Issue 15(2016) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THU0353 AN ORALLY AVAILABLE HIGHLY SELECTIVE 5-HYDROXYTRYPTAMINE 2B (5-HT2B) RECEPTOR ANTAGONIST AMELIORATING PULMONARY AND DERMAL FIBROSIS IN PRECLINICAL MODELS OF SYSTEMIC SCLEROSIS. (June 2019) Authors: Wenglén, Christina; Arozenius, Helena; Pettersson, Lars; Ekstrom, Gunilla Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 457 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗